All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @fox.fit1 on TikTok · 88s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @fox.fit1's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00You're going to gain back 95% of your weight and fat.
  2. 0:02If you take Ozempic, you're going to end up fatter than you were before you took the drug.
  3. 0:05And that goes for all GLP's, GIP's, Terzapatide, Mondrao, Wavy, all of them.
  4. 0:10So the data is out. The studies are out. You can Google these. You can look them up.
  5. 0:12You don't need to just take my word for it. So what it's showing is on average,
  6. 0:16these people that are losing weight are losing 40% of that in muscle tissue.
  7. 0:19And I've been telling people this over and over and over. They don't listen.
  8. 0:22So we'll put that in perspective. If you lost 100 pounds, 40 pounds of that is going to be muscle
  9. 0:27tissue, which that alone is alarming. You want more muscle tissue, not less.
  10. 0:31Okay. It's directly correlated to longevity. It's directly correlated to you burning more
  11. 0:34calories on a day to day basis because you have more muscle mass. Okay. But we'll talk about that
  12. 0:38later. Now, the other alarming fact is that on average, as soon as you come off this drug,
  13. 0:43you start gaining it back. And it's not if you take get off of it, it's when,
  14. 0:46because there's no long term studies. So when they get off the drug, they're on average,
  15. 0:49gaining back two pounds per month. Okay. That's a lot. But after 18 months,
  16. 0:53they're on average, gaining back all of that weight. But here's the scary part, guys,
  17. 0:57of all the weight gained back, and is 95% fat. So you lost 100 pounds, 40 pounds of that was,
  18. 1:03you know, muscle. So now you're gaining back to 100 pounds, but 95 pounds of it is fat. So you
  19. 1:08lost all this muscle tissue and you're not getting it back. And now the way to combat that, just have
  20. 1:12a good adequate nutrition, get enough protein in and have a weightlifting program. Otherwise,
  21. 1:15you will lose muscle. There's no question about it. So if you are currently taking these drugs
  22. 1:19or thinking about it and you want some information, shoot me a DM, I can have a conversation with
  23. 1:23you about it and tell you exactly how to combat a lot of the negative side effects that we do not want.

Does Ozempic cause rebound weight gain without exercise?

Dustin Fox

TikTok creator

30.5K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide produce clinically significant weight loss, but discontinuation is associated with substantial weight regain driven by reversal of appetite suppression and hormonal changes, as documented in the STEP 1 extension trial (Wilding et al., 2022). Lean mass loss during treatment is a documented concern, estimated at roughly 25-39% of total weight lost, and is substantially mitigated by resistance training and higher protein intake. Patients considering stopping or starting GLP-1 therapy should consult a licensed clinician, as individual metabolic profiles, comorbidities, and medication history all affect appropriate management.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Does Ozempic cause rebound weight gain without exercise?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Does Ozempic cause rebound weight gain without exercise?" from Dustin Fox. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide produce clinically significant weight loss, but discontinuation is associated with substantial weight regain driven by reversal of appetite suppression and hormonal changes, as documented in the STEP 1 extension trial (Wilding et al.

The reason this review is not generic is the source wording and the canonical claim label "glp1 people relying on ozempic or other glp 1 medications with." In this clip, the useful excerpt is: "You're going to gain back 95% of your weight and fat." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Lean mass loss during GLP-1 therapy is estimated at 25-39% of total weight lost across published DEXA scan data, not a fixed 40% for all users.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide produce clinically significant weight loss, but discontinuation is associated with substantial weight regain driven by reversal of appetite suppression and hormonal changes, as documented in the STEP 1 extension trial (Wilding et al.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide produce clinically significant weight loss, but discontinuation is associated with substantial weight regain driven by reversal of appetite suppression and hormonal changes, as documented in the STEP 1 extension trial (Wilding et al., 2022). Lean mass loss during treatment is a documented concern, estimated at roughly 25-39% of total weight lost, and is substantially mitigated by resistance training and higher protein intake. Patients considering stopping or starting GLP-1 therapy should consult a licensed clinician, as individual metabolic profiles, comorbidities, and medication history all affect appropriate management.
  • The STEP 1 extension trial (Wilding et al., 2022, NEJM) confirmed that most weight lost on semaglutide is regained within about 12 months of stopping, driven by reversal of appetite-suppressing hormonal effects.
  • Lean mass loss during GLP-1 therapy is estimated at 25-39% of total weight lost across published DEXA scan data, not a fixed 40% for all users.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The STEP 1 extension trial (Wilding et al., 2022, NEJM) confirmed that most weight lost on semaglutide is regained within about 12 months of stopping, driven by reversal of appetite-suppressing hormonal effects.
  • Lean mass loss during GLP-1 therapy is estimated at 25-39% of total weight lost across published DEXA scan data, not a fixed 40% for all users.
  • The '95% fat regain' figure circulating in fitness content is drawn from limited studies and should not be treated as a universal, settled statistic.
  • The SELECT trial (Lincoff et al., 2023, NEJM) followed 17,604 patients for a median of 33 months, meaning the claim that no long-term GLP-1 data exists is factually outdated.
  • Resistance training and adequate protein intake are evidence-backed strategies to reduce lean mass loss during GLP-1 therapy, a point the creator made correctly.
  • Weight regain after stopping GLP-1 drugs reflects pharmacology, not personal failure. The drugs alter appetite hormones, and stopping them reverses that effect.
  • Any decision to start, adjust, or stop a GLP-1 medication should involve a licensed clinician with access to your full health history, not fitness content creators.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @fox.fit1 actually say?

The creator made several specific numerical claims: that GLP-1 users lose "40% of that in muscle tissue," that people who stop the drug gain back "two pounds per month," and that after 18 months, regained weight is "95% fat." The conclusion was stark: "you're going to end up fatter than you were before you took the drug." The advice wrapped around these claims, eat protein and lift weights, is sound. The numbers themselves deserve much closer inspection.

To be fair, the creator encouraged viewers to look up the studies themselves. That's a reasonable ask. So let's actually do that, because the data is more complicated than a TikTok summary allows.

Does the science back this up?

Partially, but the specific figures are distorted. The legitimate concern about muscle loss during GLP-1 therapy is real and documented. The "95% fat regain" statistic, presented as settled fact, is drawn from one study and misrepresented in ways that matter.

The most cited source for rebound weight gain is Wilding et al. (2022, New England Journal of Medicine), the STEP 1 trial extension. After stopping semaglutide, participants regained about two-thirds of lost weight within one year, not all of it within 18 months as stated. The composition of that regained weight, meaning how much was fat versus lean mass, was not reported as "95% fat" in that paper.

The muscle loss figure comes largely from a 2023 analysis by Iepsen et al. and commentary on DEXA scan data from multiple trials. Estimates of lean mass loss during GLP-1 therapy cluster between 25% and 39% of total weight lost, so the "40%" figure is in the right ballpark, but it varies significantly depending on whether patients also exercise and how much protein they consume. That context was missing from the video.

What did they get wrong (or right)?

They got the core concern right: GLP-1 drugs do reduce appetite in ways that can accelerate muscle loss if users are not resistance training and eating adequate protein. That is supported by the literature and is clinically relevant. Credit where it's due.

What they got wrong is the certainty of the numbers. The claim that regained weight is "95% fat" appears to originate from a small 2023 study and has been circulated heavily in fitness content, often without the caveat that it reflects a specific patient group, not a universal outcome. Presenting it as a definitive average for all GLP-1 users is misleading.

The statement that there are "no long term studies" is also outdated. The SELECT trial (Lincoff et al., 2023, NEJM) followed over 17,000 patients for a median of 33 months. Long-term data exists. It is incomplete on some questions, but the claim that it simply doesn't exist is inaccurate.

  • Muscle loss during GLP-1 use: real concern, figures are approximate not exact
  • Weight regain after stopping: documented, but timeline and composition details were overstated
  • "95% fat" regain: drawn from limited data, presented as universal fact
  • "No long term studies": inaccurate as of 2023-2024
  • Protein and resistance training advice: genuinely correct and supported by evidence

What should you actually know?

If you are using or considering a GLP-1 medication, the creator's core behavioral advice is legitimate: resistance training and adequate protein intake meaningfully reduce the proportion of weight lost that comes from lean mass. That is well-supported. The problem is that alarmist figures, even directionally correct ones, can push people to stop medications that may be appropriate for their situation without talking to a clinician first.

A 2022 paper by Cava et al. in Obesity Reviews found that combining resistance exercise with caloric restriction, including drug-induced restriction, substantially preserved lean mass compared to caloric restriction alone. The biological mechanism behind rebound weight gain is also documented: GLP-1 drugs alter appetite-regulating hormones, and those effects reverse when the drug stops. This is a pharmacological reality, not a moral failing of the patient.

The decision to start, continue, or stop a GLP-1 medication should happen in conversation with a licensed clinician who knows your full health picture, not based on a TikTok video's numerical claims, including this one. If the numbers in this video scared you, bring that conversation to your provider, not a fitness influencer's DMs.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dustin Fox · TikTok creator

30.5K views on this video

⚡️ People relying on Ozempic or other GLP-1 medications without a solid nutrition plan and resistance training are setting themselves up for rebound fat gain — and the data is already showing this tre

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 extension trial (wilding et al., 2022, nejm)?

The STEP 1 extension trial (Wilding et al., 2022, NEJM) confirmed that most weight lost on semaglutide is regained within about 12 months of stopping, driven by reversal of appetite-suppressing hormonal effects.

What does the video say about lean mass loss during glp-1 therapy?

Lean mass loss during GLP-1 therapy is estimated at 25-39% of total weight lost across published DEXA scan data, not a fixed 40% for all users.

What does the video say about the '95% fat regain' figure circulating in fitness content?

The '95% fat regain' figure circulating in fitness content is drawn from limited studies and should not be treated as a universal, settled statistic.

What does the video say about the select trial (lincoff et al., 2023, nejm) followed 17,604?

The SELECT trial (Lincoff et al., 2023, NEJM) followed 17,604 patients for a median of 33 months, meaning the claim that no long-term GLP-1 data exists is factually outdated.

What does the video say about resistance training?

Resistance training and adequate protein intake are evidence-backed strategies to reduce lean mass loss during GLP-1 therapy, a point the creator made correctly.

What does the video say about weight regain after stopping glp-1 drugs reflects pharmacology, not personal?

Weight regain after stopping GLP-1 drugs reflects pharmacology, not personal failure. The drugs alter appetite hormones, and stopping them reverses that effect.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dustin Fox, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.